Pretreatment with nebivolol attenuates level and expression of matrix metalloproteinases in a rat model of renal ischaemia–reperfusion injury

Abstract

Nebivolol attenuated IRI by decreasing the expression and level of MMP-2 and MMP-9.

The pretreatment of rats with nebivolol ameliorates bladder contractile dysfunction caused by ischemia‐reperfusion injury

“…Previous studies have indicated that nebivolol elicited protection against IR injury in different organs and tissues 12‐15 . To the best of our knowledge, the present study is the first in the literature showing the protective effect of nebivolol on rat urinary bladder contractile dysfunction caused by IR injury.…”

“…Previous studies have indicated that nebivolol elicited protection against IR injury in different organs and tissues. [12][13][14][15] To the best of our knowledge, the present study is the first in the literature showing the protective effect of nebivolol on rat urinary bladder contractile dysfunction caused by IR injury. Although therapeutic doses of nebivolol used in the animal models of hypertension range from 5 to 10 mg/kg, lower doses (0.3-2 mg/kg) have also been found to be protective against IR injury.…”

“…Nebivolol has been of potential interest regarding its protective effects due to additional antioxidant and anti‐inflammatory properties 10,11 . This notion has also been supported by other studies showing protection with nebivolol against IR injury in several organs and tissues including liver, 12 kidney, 13 heart, 14 and brain 15 . However, there is no study that evaluates the effects of nebivolol against bladder injury induced by IR insult.…”

Matrix Metalloproteinase-2 Inhibition in Acute Ischemia-Reperfusion Heart Injury—Cardioprotective Properties of Carvedilol

“…CAR and NEB were both shown to inhibit the activity of various MMPs in conditions of enhanced oxidative stress related to atherosclerosis, myocarditis, periodontitis, hypertension, or renal IR injury [11][12][13]15,16]. However, there were no data on the effect of these drugs on MMP activation in acute IR injury of the heart.…”

“…Nebivolol (NEB) is a third generation, highly selective β1-adrenoceptor antagonist endowed with the ability to induce nitric oxide release from the endothelium [14]. Moreover, it was shown to attenuate MMP-2 and MMP-9 activities in experimental renovascular hypertension and renal IR injury [15,16]. In contrast, metoprolol (MET) represents a second generation, selective β1-adrenoceptor antagonist with no pleiotropic actions disclosed.…”